{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:14:59Z","timestamp":1794507299162,"version":"4.9.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urolonc.2026.111032","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:32:04Z","timestamp":1771936324000},"page":"700-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cell-surface targets for prostate cancer therapeutics"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3676-2798","authenticated-orcid":false,"given":"Samuel","family":"Ruder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Ziaeefar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika P","family":"Jaswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.urolonc.2026.111032_bib0002","article-title":"Assessment of cell surface targets in metastatic prostate cancer: expression landscape and molecular correlates","author":"Ajkunic","year":"2023","journal-title":"Res Sq"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0003","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in Prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/ERC-18-0226","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","author":"Bakht","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.urolonc.2026.111032_bib0005","article-title":"Influence of subcellular localization on the cytotoxicity of targeted \u03b1-therapy","author":"Lee","year":"2025","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","article-title":"Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy","volume":"48","author":"Wright","year":"1996","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3892\/mmr.2023.12939","article-title":"STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide","volume":"27","author":"Rocha","year":"2023","journal-title":"Mol Med Rep"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111032_bib0008","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nature Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0009","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s40425-019-0816-5","article-title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","volume":"7","author":"MacGregor","year":"2019","journal-title":"J Immuno Ther Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111032_bib0010","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/pros.24549","article-title":"PSMA-heterogeneity in metastatic castration-resistant prostate cancer: circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy","volume":"83","author":"Derlin","year":"2023","journal-title":"Prostate"},{"issue":"23","key":"10.1016\/j.urolonc.2026.111032_bib0011","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"484","key":"10.1016\/j.urolonc.2026.111032_bib0012","doi-asserted-by":"crossref","first-page":"eaav0891","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111032_bib0013","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111032_bib0014","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ijc.2910620520","article-title":"Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas","volume":"62","author":"Fornaro","year":"1995","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111032_bib0015","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/emmm.201200222","article-title":"TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma","volume":"4","author":"Lin","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0016","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111032_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075864","article-title":"Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway","volume":"8","author":"Liu","year":"2013","journal-title":"PLOS ONE"},{"issue":"16","key":"10.1016\/j.urolonc.2026.111032_bib0018","doi-asserted-by":"crossref","first-page":"14318","DOI":"10.18632\/oncotarget.3960","article-title":"Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts","volume":"6","author":"Trerotola","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0019","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in Human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111032_bib0020","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.2910550611","article-title":"Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody","volume":"55","author":"Stein","year":"1993","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2026.111032_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105853","article-title":"TROP2 is highly expressed in cutaneous squamous cell carcinomas and a subset of adnexal carcinomas: a potential therapeutic target with TROP2-directed antibody drug conjugates","volume":"160","author":"He","year":"2025","journal-title":"Human Pathol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0022","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1073\/pnas.1905384117","article-title":"Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1","volume":"117","author":"Hsu","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0023","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41598-023-50215-z","article-title":"High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker","volume":"14","author":"Liu","year":"2024","journal-title":"Scientific Rep"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111032_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096993","article-title":"Trop-2 is a determinant of breast cancer survival","volume":"9","author":"Ambrogi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ygyno.2011.03.002","article-title":"High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody","volume":"122","author":"Varughese","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0026","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/modpathol.3801001","article-title":"TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity","volume":"21","author":"Fong","year":"2008","journal-title":"Mod Pathol"},{"issue":"3\u20134","key":"10.1016\/j.urolonc.2026.111032_bib0027","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111032_bib0028","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10585-011-9419-3","article-title":"Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver","volume":"28","author":"Thomas","year":"2011","journal-title":"Clin Exp Metastasis"},{"issue":"13","key":"10.1016\/j.urolonc.2026.111032_bib0029","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/pros.24400","article-title":"Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer","volume":"82","author":"Bray","year":"2022","journal-title":"The Prostate"},{"issue":"19","key":"10.1016\/j.urolonc.2026.111032_bib0030","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1802354115","article-title":"Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111032_bib0031","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1158\/2767-9764.CRC-22-0491","article-title":"The identification of CELSR3 and other potential cell surface targets in neuroendocrine prostate cancer","volume":"3","author":"Van Emmenis","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111032_bib0032","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","article-title":"Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.111032_bib0033","article-title":"Single cell analysis of treatment-resistant prostate cancer: implications of cell State changes for cell surface antigen targeted therapies","author":"Zaidi","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.urolonc.2026.111032_bib0034","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2025.43.16_suppl.4018","article-title":"Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study","volume":"43","author":"Lentz","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111032_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102615","article-title":"Biomarker analysis from a phase 1\/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer","volume":"63","author":"Gazzah","year":"2026","journal-title":"Transl Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111032_bib0036","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2967\/jnumed.120.252791","article-title":"Anti-CEA pretargeted immuno-PET shows higher sensitivity than DOPA PET\/CT in detecting relapsing metastatic medullary thyroid carcinoma: post hoc analysis of the iPET-MTC study","volume":"62","author":"Bodet-Milin","year":"2021","journal-title":"J Nuclear Med"},{"issue":"24","key":"10.1016\/j.urolonc.2026.111032_bib0037","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","article-title":"Preclinical activity of SAR408701: a novel Anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors","volume":"26","author":"Decary","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0038","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","article-title":"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody\u2013drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study","volume":"33","author":"Gazzah","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0039","first-page":"26","article-title":"First-In-Human pilot PET immunoimaging study of (64)Cu-anti-carcinoembryonic antigen monoclonal antibody (hT84.66-M5A) in patients with carcinoembryonic antigen-producing cancers","volume":"38","author":"Wong","year":"2023","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"10.1016\/j.urolonc.2026.111032_bib0040","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2967\/jnumed.123.267107","article-title":"CEACAM5-Targeted immuno-PET in androgen receptor-negative prostate cancer","volume":"65","author":"Imberti","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0041","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am J Clin Exp Immunol"},{"issue":"24","key":"10.1016\/j.urolonc.2026.111032_bib0042","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.2174\/0929867326666190517115515","article-title":"B7-H3 Immune checkpoint protein in Human cancer","volume":"27","author":"Flem-Karlsen","year":"2020","journal-title":"Curr Med Chem"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111032_bib0043","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer - beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111032_bib0044","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-H3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/pcan.2016.49","article-title":"Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis","volume":"20","author":"Benzon","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111032_bib0047","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41391-021-00331-6","article-title":"Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer","volume":"24","author":"Amori","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111032_bib0048","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/pros.24180","article-title":"Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer","volume":"81","author":"Nunes-Xavier","year":"2021","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0049","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41420-023-01453-7","article-title":"B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discovery"},{"issue":"14","key":"10.1016\/j.urolonc.2026.111032_bib0050","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for Human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0051","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/74307","article-title":"Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis","volume":"24","author":"Bulman","year":"2000","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111032_bib0052","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3390\/jcm8091277","article-title":"Updates on the role of molecular alterations and NOTCH signalling in the development of neuroendocrine neoplasms","volume":"8","author":"von Arx","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0053","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/1078-0432.CCR-18-2312","article-title":"Cell surface notch Ligand DLL3 is a therapeutic target in isocitrate dehydrogenase-mutant glioma","volume":"25","author":"Spino","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0054","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","article-title":"Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer","volume":"83","author":"Chou","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2026.111032_bib0055","article-title":"First-in-human imaging with [(89)Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate","author":"Tendler","year":"2024","journal-title":"medRxiv"},{"key":"10.1016\/j.urolonc.2026.111032_bib0056","article-title":"STEAP proteins: roles in disease biology and potential for therapeutic intervention","volume":"309","author":"Cai","year":"2025","journal-title":"Int J Biologic Macromolecul"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111032_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220456","article-title":"Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer","volume":"14","author":"Burnell","year":"2019","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.urolonc.2026.111032_bib0058","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.3390\/cancers14164034","article-title":"STEAP1-4 (six-transmembrane epithelial antigen of the prostate 1-4) and their clinical implications for prostate cancer","volume":"14","author":"Xu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.08.028","article-title":"STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score","volume":"32","author":"Gomes","year":"2014","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111032_bib0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12032-018-1100-0","article-title":"Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens","volume":"35","author":"Gomes","year":"2018","journal-title":"Med Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.111032_bib0061","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.118.222844","article-title":"Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody","volume":"60","author":"Carrasquillo","year":"2019","journal-title":"J Nucl Med"},{"issue":"17","key":"10.1016\/j.urolonc.2026.111032_bib0062","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121497","article-title":"Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer","volume":"3","author":"Su","year":"2018","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111032_bib0063","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.urology.2005.06.094","article-title":"Analysis of membrane-bound complement regulatory proteins in prostate cancer","volume":"66","author":"Loberg","year":"2005","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111032_bib0064","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-20-3310","article-title":"Molecular imaging of prostate cancer targeting CD46 using ImmunoPET","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-023-02636-x","article-title":"CD46 targeted (212)Pb alpha particle radioimmunotherapy for prostate cancer treatment","volume":"42","author":"Li","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.urolonc.2026.111032_bib0066","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO-24-01989","article-title":"Phase I, first-in-Human study of FOR46 (FG-3246), an immune-modulating antibody-drug conjugate targeting CD46, in patients with metastatic castration-resistant prostate cancer","volume":"43","author":"Aggarwal","year":"2025","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.urolonc.2026.111032_bib0067","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1158\/1078-0432.CCR-24-2850","article-title":"Effective treatment of disseminated prostate cancer using CD46-targeted 225Ac therapy","volume":"31","author":"Bidkar","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111032_bib0068","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1160\/TH13-04-0275","article-title":"Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. established relevance and emerging roles","volume":"110","author":"Thorek","year":"2013","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0069","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3390\/ijms25042222","article-title":"Genomic and immunologic correlates in prostate cancer with high expression of KLK2","volume":"25","author":"Paniagua-Herranz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.111032_bib0070","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1200\/JCO.2025.43.16_suppl.5050","article-title":"Molecular and clinical characterization of KLK2 mRNA expression in prostate cancer (PC)","volume":"43","author":"McKay","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.111032_bib0071","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.2024.42.4_suppl.202","article-title":"Preclinical characterization of human kallikrein 2 (hK2) as a novel target for the treatment of prostate cancer","volume":"42","author":"Shen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.urolonc.2026.111032_bib0072","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-09-3169","article-title":"Prostate stem cell antigen: a Jekyll and Hyde molecule?","volume":"16","author":"Saeki","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111032_bib0073","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.onc.1203426","article-title":"Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer","volume":"19","author":"Gu","year":"2000","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111032_bib0074","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s11307-020-01518-4","article-title":"Evaluation of [(131)I]I- and [(177)Lu]Lu-DTPA-A11 minibody for radioimmunotherapy in a preclinical model of PSCA-expressing prostate cancer","volume":"22","author":"Tsai","year":"2020","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111032_bib0075","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/annonc\/mds078","article-title":"A phase I\/IIA study of AGS-PSCA for castration-resistant prostate cancer","volume":"23","author":"Morris","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0076","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2387240","article-title":"Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer","volume":"16","author":"Chu","year":"2024","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0077","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0925-4439(97)00032-X","article-title":"Molecular cloning of seprase: a serine integral membrane protease from human melanoma","volume":"1361","author":"Goldstein","year":"1997","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111032_bib0078","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/genes13010135","article-title":"Expression of fibroblast activation protein is enriched in neuroendocrine prostate cancer and predicts worse survival","volume":"13","author":"Vlachostergios","year":"2022","journal-title":"Genes (Basel)"},{"issue":"12","key":"10.1016\/j.urolonc.2026.111032_bib0079","first-page":"1952","article-title":"FAP and PSMA expression by immunohistochemistry and PET imaging in castration-resistant prostate cancer: a translational pilot study","volume":"65","author":"Huang","year":"2024","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111032_bib0080","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/pharmaceutics17050552","article-title":"The development of Al(18)F-NOTA-FAP-2286 as an FAP-targeted PET tracer and the translational application in the diagnosis of acquired drug resistance in progressive prostate cancer","volume":"17","author":"Du","year":"2025","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0081","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111032_bib0082","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/00313029500169033","article-title":"Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer","volume":"27","author":"Cohen","year":"1995","journal-title":"Pathology"},{"issue":"19","key":"10.1016\/j.urolonc.2026.111032_bib0083","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.3390\/cancers16193262","article-title":"Revisiting HER2 in prostate cancer from an inclusive perspective: from biomarkers to omics","volume":"16","author":"Mavingire","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.urolonc.2026.111032_bib0084","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0085","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.10339","article-title":"HER-2 profiling and targeting in prostate carcinoma","volume":"94","author":"Morris","year":"2002","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111032_bib0086","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1158\/2767-9764.CRC-25-0069","article-title":"Patterns of HER2 expression in metastatic prostate and urothelial cancers: implications for HER2-targeted therapies","volume":"5","author":"Lee","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111032_bib0087","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-13-1549","article-title":"Molecular pathways: HER3 targeted therapy","volume":"20","author":"Gala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.111032_bib0088","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2024.42.16_suppl.5019","article-title":"Prevalence of HER3 expression in prostate adenocarcinoma and its clinicopathological characteristics","volume":"42","author":"Rajendran","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.111032_bib0089","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1158\/1078-0432.CCR-23-2161","article-title":"ERBB3 Overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature","volume":"30","author":"Vellky","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.urolonc.2026.111032_bib0090","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 Is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.urolonc.2026.111032_bib0091","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1080\/14796694.2025.2561539","article-title":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.111032_bib0092","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1111\/jcmm.16497","article-title":"Systematic expression analysis of the CELSR family reveals the importance of CELSR3 in human lung adenocarcinoma","volume":"25","author":"Li","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111032_bib0093","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3892\/ol.2020.11671","article-title":"Elevated CELSR3 expression is associated with hepatocarcinogenesis and poor prognosis","volume":"20","author":"Ouyang","year":"2020","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111032_bib0094","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.7150\/jca.39328","article-title":"Effect of CELSR3 on the cell cycle and apoptosis of hepatocellular carcinoma cells","volume":"11","author":"Xie","year":"2020","journal-title":"J Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111032_bib0095","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.7150\/jca.49567","article-title":"Increased expression of CELSR3 indicates a poor prognostic factor for prostate cancer","volume":"12","author":"Chen","year":"2021","journal-title":"J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.111032_bib0096","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e17161","article-title":"The anti-STEAP1\/PSMA ADC, DXC008: assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:21:10Z","timestamp":1789759270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":96,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1078143926000438"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111032","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell-surface targets for prostate cancer therapeutics","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}